Advertisement

Topics

IDRI to Continue Development of Inhalable Tuberculosis Drug Candidate

09:52 EDT 24 Aug 2017 | PharmPro

The Infectious Disease Research Institute, on behalf of the Lilly TB Drug Discovery Initiative, has entered into an agreement with a China-based biopharmaceutical company to continue development of inhalable CPZEN-45.
Contributed Author: 
Infectious Disease Research Institute (IDRI)

Original Article: IDRI to Continue Development of Inhalable Tuberculosis Drug Candidate

NEXT ARTICLE

More From BioPortfolio on "IDRI to Continue Development of Inhalable Tuberculosis Drug Candidate"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...